Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.    

"We believe that the clinical trial results to be shared at ESMO 2012 substantially enhance our knowledge of both marketed and investigational therapies from our lung and kidney cancer portfolios," said Mace Rothenberg, MD, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "We are especially pleased to be able to share, for the first time, detailed results of PROFILE 1007, a randomized trial comparing XALKORI to standard chemotherapy in patients with recurrent, ALK-positive non-small cell lung cancer (NSCLC). These results, which will be presented at the Presidential Symposium, reinforce the value of Pfizer's precision medicine approach to drug development, and demonstrate the benefit that targeted, efficient and science-driven cancer drug development can have on patient outcomes."

Treating Lung Cancer Through a Targeted Approach

Data highlights relating to Pfizer's lung cancer portfolio include:

  • Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced, ALK-positive NSCLC (PROFILE 1007) (Presidential Symposium, Abstract #LBA1, September 30, 16:00-18:00)     
  • Updated results of a global Phase 2 study with crizotinib in advanced ALK-positive NSCLC (Poster Discussion, Abstract #1230PD, September 30, 12:45-14:15)
  • Clinical activity of crizotinib in patients with advanced NSCLC harboring ROS1 gene rearrangement (Poster Discussion, Abstract #1191PD, September 30, 12:45-14:15)     

Updated data will be presented on dacomitinib, an investigational, irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant, HER2-mutant or amplified lung cancers (Oral Presentation, Abstract #1228O, September 30, 9:00-11:00). Additionally, data from a Phase 1 trial of dacomitinib in combination with XALKORI (crizotinib) in previously treated advanced NSCLC will be presented (Poster Presentation, Abstract #1290P, September 29, 13:00-14:00).   


Pfizer Oncology


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
MR-guided focused ultrasound can safely deliver antibody therapy to Her2-positive brain metastases